In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Choice of balloon-expandable versus self-expanding transcatheter aortic valve impacts hemodynamics differently according to aortic annulus size

Session Poster session 3

Speaker Ron Waksman

Congress : ESC Congress 2016

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease - Clinical
  • Session type : Poster Session
  • FP Number : P2761

Authors : R Waksman (Washington,US), T Rogers (Washington,US), A Steinvil (Washington,US), R Torguson (Washington,US), J Gai (Washington,US), E Koifman (Washington,US), S Kiramijyan (Washington,US), L Satler (Washington,US), I Ben-Dor (Washington,US), A Pichard (Washington,US)

R. Waksman1 , T. Rogers1 , A. Steinvil1 , R. Torguson1 , J. Gai1 , E. Koifman1 , S. Kiramijyan1 , L. Satler1 , I. Ben-Dor1 , A. Pichard1 , 1Washington Hospital Center - Washington - United States of America ,

European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 559-560

Background: Aortic annulus size impacts valve hemodynamics and clinical outcomes after transcatheter aortic valve replacement (TAVR). However, it is not known whether the selection of balloon-expandable valve (BEV) versus self-expanding valve (SEV) affects hemodynamics differently in patients with small, medium or large aortic annulus.

Methods: Consecutive patients undergoing TAVR with a balloon-expandable or self-expanding valve at Washington Hospital Center between 2013 and 2015 were included. Data were prospectively collected, including baseline and procedural characteristics, 30-day and 1-year mortality. Patients were grouped into tertiles based on CT angiography-derived aortic annulus perimeter measured in systole. The pre-discharge echocardiogram was analyzed for prosthetic valve hemodynamics.

Results: 193 patients were included in the study. Patients with small aortic annulus were more likely female, with lower body surface area, and smaller iliac arteries. Tertile perimeter cutoffs were 73mm and 80mm. STS score decreased as annulus size increased (7.8% vs. 7.6% vs. 6.0%, p=<0.05 for small, medium and large annulus respectively). In patients with small annulus, SEV was associated with significantly higher dimensionless index (0.64 vs. 0.53, p=0.02) and lower peak velocity (1.8 vs. 2.4m/sec, p<0.001), and a trend towards lower mean gradient (7.5 vs. 10.0mmHg, p=0.07) compared with BEV. These differences were attenuated and absent in patients with medium and large annulus respectively. Very few patients had moderate/severe paravalvular leak, with no significant association with valve type or annulus size. There was no difference in mortality between tertiles or valve type at 30 days or 1 year. There was no association between aortic annulus perimeter and 1-year mortality by univariate analysis (HR 1.00, 95% CI 0.95–1.05, p=0.86) or multivariate analysis (HR 1.02, 95% CI 0.95–1.09, p=0.60).

Conclusions: In patients with small aortic annulus, SEV hemodynamics are superior to BEV. This difference is diminished in patients with larger aortic annulus. This study highlights the importance of TAVR valve selection in patients with small aortic annulus.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are